Cipla FY26 revenue hits record ₹28,163 cr; stock +5%

Stock jumps after FY26 record revenue print

Cipla shares climbed nearly 5% on Wednesday, May 13, after the company reported its highest-ever annual revenue for fiscal 2026. The stock hit an intraday high of ₹1,353.80 on the NSE. Around 13:45 PM, Cipla was trading at ₹1,349.4, up 4.5% from the previous close of ₹1,292.30. The move came even as the March quarter showed pressure on operating profitability and net profit. Investors appeared to focus on the annual revenue record and commentary on progress in key markets. The earnings release also included updates on India and North America performance.

FY26 headline numbers: revenue up, EBITDA down

For the full FY26, Cipla’s revenue from operations stood at ₹28,163 crore, up 2.23% from ₹27,548 crore in the previous fiscal. The company described this as its highest-ever yearly revenue. FY26 EBITDA fell 17% to ₹5,925 crore from ₹7,128 crore in FY25. The article text carried two different statements on FY26 profit after tax: one section said profit after tax stood at ₹5,273 crore compared with ₹3,879 crore in the previous fiscal, while another line stated net profit fell to ₹3,879 crore from ₹5,273 crore in the previous fiscal. The revenue and EBITDA figures were consistently reported across the text. Management commentary positioned the revenue record as evidence of core business resilience, while acknowledging near-term challenges in certain markets.

Q4FY26: revenue dips, margin compresses

In the March 2026 quarter, Cipla reported total income from operations of ₹6,541 crore, down 2.8% year-on-year from ₹6,730 crore in the year-ago period. EBITDA dropped 35.17% to ₹997 crore in Q4FY26 from ₹1,538 crore a year earlier. EBITDA margin declined to 15.2% from 22.8%. Profit after tax for the quarter came in at ₹555 crore, down 54.6% from ₹1,222 crore in March 2025. The quarter’s numbers show a sharper fall in profitability than the decline in revenue, reflecting margin pressure. The combination of lower EBITDA and a steep profit drop typically draws scrutiny on cost trends, product mix, and geography-wise performance.

One India business: growth stays strong

Cipla’s India business was highlighted as a key support in the quarter. The report said the One India business grew 15% year-on-year during the quarter, with all three segments delivering double-digit growth. It also stated that One India includes prescription drugs, trade generics, and consumer health. In the March 2026 quarter, India revenue was reported at ₹3,007 crore, up 15%. Separately, management said the One India business surpassed the ₹12,500 crore annual revenue milestone. These datapoints were presented alongside the weaker consolidated quarterly profitability, indicating that domestic growth did not fully offset pressures elsewhere.

North America: mixed indicators across disclosures

The update on North America included multiple datapoints in the provided text. One section said Cipla’s North America business delivered quarterly revenue of $155 million, supported by demand in the differentiated portfolio and a steady base business. Another section, in Hindi, said North America revenue declined 26% to ₹1,414 crore in the quarter. The same Hindi section added that Cipla’s US facility received regulatory approval for a generic version of ‘gVentolin’. Taken together, the disclosures point to continued focus on the US portfolio and regulatory progress, while also indicating that the quarter may have seen pressure in the region on a reported basis.

Dividend announced: ₹13 per share, record date June 5

Despite the sharp year-on-year fall in quarterly profit, Cipla’s board recommended a final dividend of ₹13 per share for FY 2025-26, as reported in the Hindi portion of the text. The record date for the dividend was set as June 5. Dividend announcements often matter to investors looking for cash returns, especially when near-term earnings are volatile. The stock’s rise on the results day suggests the market weighed the record annual revenue, business updates, and dividend alongside the weak Q4 profitability.

Management commentary: progress amid near-term challenges

Achin Gupta, managing director and global chief executive officer at Cipla, said the company continues to make considerable progress across its focused markets. He said FY26 delivered the highest-ever yearly revenue of ₹28,163 crore, reflecting strength in core businesses despite certain markets facing near-term challenges. He also highlighted the One India milestone of surpassing ₹12,500 crore in annual revenue. The remarks, as carried in the report, emphasised execution in focus markets rather than offering specific forward guidance.

Market context: stock still down YTD

Even after the May 13 jump, Cipla’s stock remained under pressure on a year-to-date basis. The report said Cipla had declined around 14.5% YTD, compared with an 11% decline in the Nifty50 over the same period. This gap suggests the stock entered the results with a weaker recent performance than the benchmark. The sharp intraday gain indicates the results and disclosures were viewed as incrementally positive relative to expectations for annual revenue and business momentum. At the same time, the Q4 margin compression and profit decline remained key counters in the same release.

Key numbers at a glance

Why the earnings day move matters

Cipla’s results presented a clear split between annual revenue momentum and quarterly profitability pressure. A record FY26 revenue print of ₹28,163 crore provided a headline positive, but FY26 EBITDA declined and the March quarter showed a steep drop in EBITDA, margin, and profit. The stock reaction suggests investors prioritised the annual top-line milestone, India business growth, and the dividend signal. However, the scale of margin compression in Q4FY26 puts attention on the sustainability of operating performance in subsequent quarters.

Conclusion

Cipla shares rallied nearly 5% as the company reported its highest-ever annual revenue in FY26 and announced a ₹13 per-share dividend with a June 5 record date. The same release also showed Q4FY26 margin pressure, with EBITDA and profit falling sharply year-on-year. Investors will track how Cipla balances growth in India and portfolio progress in North America alongside the need to stabilise operating profitability in the coming quarters.